Regeneron

News

Verona’s first-in-class COPD drug ‘could transform market’

Verona Pharma has claimed FDA approval for its chronic obstructive pulmonary disease (COPD) drug ensifentrine, which has been tipped as a future blockbuster.

News

Novartis cues up filings for remibrutinib in chronic hives

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – a

News

Dupixent nears EU approval for COPD, as FDA delays

Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chr

News

Regeneron gene therapy restores hearing in deaf child

Regeneron’s gene therapy for otoferlin-related hearing loss – a genetic cause of deafness – has restored hearing to normal levels in one profoundly deaf child within just

R&D

Life sciences in Ireland: Nurturing talent, innovating excel...

Late last month, pharmaphorum was invited on an IDA Ireland-organised press tour of the life sciences industry in Ireland’s West, permitting an inside peek into the world-class life science

News

Regeneron launches $500m venture capital arm

Regeneron has formed a corporate venture capital unit with $100 million a year to invest over the next five years in “biopharmaceutical, healthcare, and health technology”

Verona’s first-in-class COPD drug ‘could transform market’

Novartis cues up filings for remibrutinib in chronic hives

Dupixent nears EU approval for COPD, as FDA delays

Regeneron gene therapy restores hearing in deaf child

Life sciences in Ireland: Nurturing talent, innovating excel...

Regeneron launches $500m venture capital arm

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Regeneron

Editor's Picks